Glucevia®, a Fraxinus angustifolia Vahl extract, is able to modify the gut microbiota composition and those effects are correlated with steatosis severity in obese and diabetic mice

Nonalcoholic fatty liver disease (NAFLD) is a condition defined by excessive fat (triglycerides) accumulation (u003e 5%) in the liver that could evolve to nonalcoholic steatohepatitis (NASH) with liver cell injury and inflammation and increased risks of cirrhosis, liver failure, and hepatocellular carcinoma. NASH is widely considered to be the liver expression of the metabolic syndrome and it is now estimated that about 30% of all adults have NAFLD and 2%–6% of adults have NASH in the US and Western countries and that NAFLD is affecting up to 70–80% of obese individuals. Alteration of the ecologic organization of the gut microbiota, named dysbiosis, have been found to be related with several clinical conditions such as obesity, diabetes and NAFLD. We have previously demonstrated that Glucevia®, a Fraxinus angustifolia Vahl samara extract, is able to improve glucose tolerance in healthy humans and also to improve fasting blood glucose, circulating triglycerides and steatosis in diabetic animals. Here, we aimed...